Pediatric Hodgkin lymphoma- biomarkers, drugs, and clinical trials for translational science and medicine
| Autor: | Nicole Carroll, Themba Nyrenda, Pritish K. Bhattacharyya, Andre Goy, Nehad M. Ayoub, Betty Tai, Tatsunari Tomiyama, Michael E. Harris, K. Stephen Suh, Poonam Nagpal, Andrew L. Pecora, Mohamed R. Akl, Tasheka Cousins |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Oncology medicine.medical_specialty Pathology Adolescent CD30 Antineoplastic Agents Review Translational Research Biomedical 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine Epidemiology Biomarkers Tumor Genetic predisposition medicine tumor microenvironment Humans Child Brentuximab vedotin Clinical Trials as Topic business.industry Mortality rate Hodgkin Disease Clinical trial pediatric Child Preschool 030220 oncology & carcinogenesis biomarker Biomarker (medicine) Female business Hodgkin lymphoma 030215 immunology medicine.drug |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.11509 |
| Popis: | Hodgkin lymphoma (HL) is a lymphoid malignancy that is typically derived from germinal-center B cells. EBV infection, mutations in NF-κB pathway genes, and genetic susceptibility are known risk factors for developing HL. CD30 and NF-κB have been identified as potential biomarkers in pediatric HL patients, and these molecules may represent therapeutic targets. Although current risk adapted and response based treatment approaches yield overall survival rates of >95%, treatment of relapse or refractory patients remains challenging. Targeted HL therapy with the antibody-drug conjugate Brentuximab vedotin (Bv) has proven to be superior to conventional salvage chemotherapy and clinical trials are being conducted to incorporate Bv into frontline therapy that substitutes Bv for alkylating agents to minimize secondary malignancies. The appearance of secondary malignancies has been a concern in pediatric HL, as these patients are at highest risk among all childhood cancer survivors. The risk of developing secondary leukemia following childhood HL treatment is 10.4 to 174.8 times greater than the risk in the general pediatric population and the prognosis is significantly poorer than the other hematological malignancies with a mortality rate of nearly 100%. Therefore, identifying clinically valuable biomarkers is of utmost importance to stratify and select patients who may or may not need intensive regimens to maintain optimal balance between maximal survival rates and averting late effects. Here we discuss epidemiology, risk factors, staging, molecular and genetic prognostic biomarkers, treatment for low and high-risk patients, and the late occurrence of secondary malignancies in pediatric HL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|